EMA
The FDA granted Orphan Drug Designation to tamibarotene for the treatment of MDS in February 2022.
The EMA’s CHMP recommendation is based on positive results from the multicohort, open-label...
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use issued...
Advertisement
The European Medicines Agency validated a type II variation for the extension of the indication for lisocabtagene maraleucel ...
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use recommended the conditional approval ...
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.